Kestra Private Wealth Services
TELO icon

Kestra Private Wealth Services’s Telomir Pharmaceuticals TELO Stock Holding History

Kestra Private Wealth Services’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1K Hold
11,000
– – ﹤0.01% 1805
2026
Q1 		$14.3K Hold
11,000
– – ﹤0.01% 1747
2025
Q4 		$14.6K Hold
11,000
– – ﹤0.01% 1716
2025
Q3 		$15.3K Buy
+11,000
New +$16.6K ﹤0.01% 1660

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
World Investment Advisors
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Kestra Private Wealth Services's TELO Position: Q2 2026 in Review

Kestra Private Wealth Services held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 11,000 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1805.

Kestra Private Wealth Services first reported a position in TELO in Q3 2025 and has held it in 4 quarters since. The position peaked at $15.3K in Q3 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Kestra Private Wealth Services held 11,000 shares of Telomir Pharmaceuticals worth $14.1K as of Q2 2026.
  • Kestra Private Wealth Services left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1805 holding.
  • Kestra Private Wealth Services first reported a position in Telomir Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Kestra Private Wealth Services's Telomir Pharmaceuticals position peaked at $15.3K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.